Tag: the wellness company

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Research Literacy Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treratments Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Pancreatic Cancer Repurposed Drug Studies Research News & Updates Wellness Company

How Cancer Patients and Caregivers Should Evaluate Viral Claims About Unproven Treatments

Hulscher 2026 Study and how claims can go viral

The article from Courage Against Cancer emphasizes the importance of critically evaluating cancer treatment claims, particularly viral studies like the 2026 Hulscher et al. ivermectin-mebendazole paper. It provides a structured framework for assessing study validity, distinguishing between preclinical and clinical evidence, and understanding potential conflicts of interest to make informed treatment decisions.

Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Research Literacy Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Treatment Research & Critical Analysis Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Hulscher Study Integrative Oncology Insights Ivermectin Mebendazole Non-Chemo Cancer Treatments Pancreatic Cancer Repurposed Drug Studies Research News & Updates Wellness Company

NCI Ivermectin Research vs. the Hulscher Study: Two Completely Different Things

NCI and Hulscher Study Critique

Courage Against Cancer clarifies the distinction between the legitimate preclinical research conducted by the NCI on ivermectin and the controversial Hulscher observational study. The latter’s findings are compromised due to bias and conflicts of interest. Conflating the two may mislead patients, potentially exploiting their vulnerability and delaying effective treatments.

Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment Research & Critical Analysis Cancer Wellness Protocols Drug Repurposing & Innovation Health & Wellness Hulscher Study Ivermectin Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company

Breaking Down the Study Design: Why Observational and Self-Reported Data Have Serious Limits

Why Observational Self Reported data have serious limits

Courage Against Cancer critiques the methodology of the Hulscher et al. study on cancer treatment, emphasizing the weaknesses of observational design and self-reported outcomes. It highlights issues like lack of randomization, potential bias, and conflicts of interest, stressing that results cannot reliably inform clinical decisions and urging patients to consult oncologists about research before acting.

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Outcomes Cancer Treatment Guidance Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Fenbendazole Gut-Microiome Health & Wellness Integrative Oncology Insights Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company

What Does an 84.4% ‘Clinical Benefit Rate’ Actually Mean — and What It Doesn’t

84 percent clinical benefit rate

Courage Against Cancer critiques the 2026 study by Hulscher et al., which claims an 84.4% clinical benefit rate from self-reported outcomes about off-label ivermectin and mebendazole in cancer patients. The study lacked control and independent verification, raising concerns over reliability and potential conflicts of interest. Caution is advised before drawing conclusions from such data.

Categories
Anti Cancer Breakthrough Therapies Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Treratments Clinical Trials & Cancer Treatment Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study Ivermectin Non-Chemo Cancer Treatments preclinical trial Repurposed Drug Studies Research News & Updates Wellness Company

What is clinical trial NCT05318469 and what does it study regarding ivermectin and cancer?

The trial NCT05318469 evaluates ivermectin as an adjunct therapy for metastatic triple-negative breast cancer, adhering to rigorous clinical standards. It contrasts with the controversial 2026 Hulscher et al. study, which raised concerns about methodological integrity. Ivermectin remains unapproved for cancer treatment, emphasizing the need for credible research contexts.